Track topics on Twitter Track topics that are important to you
Novartis announced a new post-hoc analysis of the phase 3 heart failure study, Paradigm-HF, which demonstrated treatment with Entresto helped to preserve kidney function, as assessed by estimated glomerular filtration rate, in patients with heart failure with reduced ejection fraction. The findings of the analysis are published in The Lancet Diabetes & Endocrinology.
According to a company press release, the analysis showed patients with heart failure with reduced ejection fraction (HFrEF) treated with Entresto (sacubitril/valsartan, Novartis), a twice-a-day medicine that reduced the
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...
Chronic kidney disease (CKD), also known as chronic renal disease, is a progressive loss in renal function over a period of months or years. The symptoms of worsening kidney function are non-specific, and might include feeling generally unwell and experi...